News Updates

More Articles Back to Article

Revitalizing European API production through reshoring

The European Union has published a report examining the advantages and disadvantages of bringing active pharmaceutical ingredient manufacturing back to EU member states, given that in 2019, Europe had almost 36% of API manufacturing sites while Asia had 55%. The report recommends evaluating the viability of relocating essential APIs to Europe, ensuring a steady supply of APIs not solely aimed at preventing shortages, while considering both regulatory and administrative processes in addition to financial incentives. Endpoints News (free registration) (3/14)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!